Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GSK2330811 in Healthy Subjects
NCT02386436Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2015
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gsk2330811 in systemic sclerosis (SSc) (6 arms), sponsored by GSK. Primary endpoints: Number of subjects with adverse events (AEs) and serious adverse events (SAEs), Composite of clinical laboratory tests: clinical chemistry, hematology and urinalysis and 2 more. Started Apr 2015; status: completed.
02
Drugs
gsk2330811
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT02386436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386436.